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A lipocortin-like, phospholipase 4 inhibitory 33 kDa protein was purified from guinea pig neutrophils. From amino 
acid composition and sequence data, this protein was found to have a high degree of homology to human lipocortin 
I. This protein inhibited porcine pancreatic phospholipase 4 activity in the presence of PH]oleic acid-labeled Escherichia 
coli membranes as substrate. Maximal inhibition amounted to 65% whereas 50% inhibition occurred at 83.5 nM. This 
protein showed F-actin-binding ability in a Ca2+-dependent manner. 
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1. INTRODUCTION 
The anti-inflammatory action of glucocorticoids 
has been attributed to the induction of a group of 
phospholipase AZ (PLA2) inhibitory proteins, col- 
lectively called lipocortin [l-6]. Lipocortin-like 
proteins have also been isolated as Ca2+-dependent 
phospholipid-binding proteins [7,8] from various 
cells such as human monocytes [9], rat 
macrophages [lo], rabbit neutrophils [3], rat renal 
medullary cell [6,11], human fibroblasts [12], 
splenic lymphocytes [13], and mouse and bovine 
thymocytes [14]. Recent work has revealed that 
there are two types of lipocortin (I and II): type I 
is monomeric and type II tetrameric, forms which 
are identical to calpactin II and I, respectively 
[ 15- 171. In addition, a 17 amino acid residue con- 
sensus sequence has been identified not only in 
lipocortins, but also in a group of other 
Ca’+-dependent phospholipid-binding proteins in- 
cluding 34 and 67 kDa calelectrins as well as en- 
donexin [ 18-211. However, the biochemical 
relationship among these proteins remains 
obscure. 
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In the previous 
tification of the 33 
paper, we reported the iden- 
kDa protein (~33) from guinea m, 
pig neutrophils as a Ca”-dependent phospholipid- 
binding protein [22]. Moreover, we demonstrated 
using a monoclonal anti-p33 antibody that this 
protein is neutrophil-specific and is translocated 
from the cytoplasm to the plasma membrane on 
treatment with various stimuli [23]. However, its 
physiological role remains obscure. Here, we 
report that p33 is closely related to human lipocor- 
tin I through the analysis of the functions, amino 
acid composition, and partial amino acid sequence 
of the protein. 
2. MATERIALS AND METHODS 
2.1. Materials 
Hartley guinea pigs were obtained from the Shizuoka 
Laboratory Animal Center (Shizuoka, Japan). Mono P, 
polybuffer 96 and polybuffer 74 were obtained from Pharmacia 
(Uppsala); C4 (5C4-300) and CNBr from Nakarai (Kyoto); TSK 
G3OOOSW from LKB (Bromma, Sweden);pBondapak Crs from 
Waters Division of Millipore (Milford, MA); [3H]oleic acid 
(8.9 Ci/mmol) from New England Nuclear (Dreieich); 
phosphatidylserine (PS, bovine brain), cardiolipin (CL, bovine 
heart), cholesterol (C), dipalmitoylphosphatidylcholine 
(DPPC) and boiGne serum albumin (BSA) from Sigma (St. 
Louis, MO); trypsin from Worthington; and PLAz from Boeh- 
ringer Mannheim. All other chemicals were of reagent grade. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 0 1988 Federation of European Biochemical Societies 131 
Volume 227, number 2 FEBS LETTERS January 1988 
2.2. Purification of p33 
A cytoplasmic fraction was prepared from guinea pig 
polymorphonuclear leukocytes (PMNs) as in [22,23]. This frac- 
tion was incubated with DPPC/C/PS or DPPC/C/CL 
(1:0.5 :0.5 molar ratio) liposomes in the presence of 1 mM 
Car% for 10 min at 4°C as described [24,25]. The liposome- 
associated proteins were separated from non-associated pro- 
teins by centrifugation at 100006 x g at 4°C for 30 min. They 
were then released from liposomes by treatment with 5 mM 
EGTA, followed by centrifugation at 100000 x g at 4°C for 
20 min. To concentrate the protein in the supernatant, solid 
(NH&S04 was added with constant stirring to a final satura- 
tion level of 100%. The mixture was allowed to stand overnight 
at 4°C and centrifuged at 100000 x g for 60 min at 4°C. The 
pellet was redissolved in a minimum volume (less than 10 ml) of 
25 mM triethanolamine-iminodiacetic acid (pH 8.3) (buffer A) 
and dialysed overnight vs two l-l volumes of buffer A. After 
dialysis, insoluble material was precipitated by centrifugation at 
100000 x g for 30 min. The supernatant was then loaded onto 
a Mono P column (200 x 5 mm) previously equilibrated with 
buffer A. Proteins were eluted with elution buffer B (10% 
polybuffer-iminodiacetic acid, pH 5.0), the flow rate being 
1.0 ml/min. The resultant fractions were analyzed by 15% 
SDS-PAGE. The p33-rich fraction was loaded onto a column 
(300 x 5 mm) of TSK G3OOOSW previously equilibrated with 
50 mM sodium phosphate buffer (pH 7.4) and eluted with the 
same buffer at a flow rate of 0.7 ml/min. 
2.3. Determination of PLA2 activity 
Samples were tested for PLAz inhibitory activity by an in 
vitro assay described by Davidson et al. [26], using [‘Hloleic 
acid-labeled Escherichia coli membranes isolated after 
autoclaving [27] with the following modifications: p33 was 
preincubated with PLA2 (50 ng) at 4°C for 10 min, followed by 
addition of E. co/i membranes and further incubation at 4°C 
for 5 min. Radioactivity of released [‘Hloleic acid was deter- 
mined as in [28]. 
2.4. F-Actin binding 
Rabbit skeletal muscle F-actin was prepared from acetone 
powder [29]. Proteins and F-actin were incubated for 1 h at 
room temperature in binding buffer (10 mM imidazole-HCI, 
pH 7.4, 2 mM MgCls, 1 mM NaNr, 0.5 mM DTT, 0.1 mM 
ATP) containing 1 mM CaCls or 1 mM EGTA with or without 
100 mM KCl. After centrifugation at 95000 rpm for 10 min in 
a Beckman TL-100 centrifuge, supernatants and pellets were 
subjected to SDS-PAGE and Coomassie blue staining. 
2.5. Amino acid analysis 
Amino acid hydrolysis of purified p33 was performed at 
110°C under vacuum in 6 M HCl for 24, 48 or 72 h. 
Hydrolysates were analyzed using a JLC-2OOA analyzer (Jeol, 
Akishima, Japan). 
2.6. Amino acid sequence analysis 
The NH*-terminal sequence of tryptic peptides and CNBr- 
cleavage peptides of p33 was determined byautomated Edman 
degradation using an Applied Biosystems model 470A gas- 
phase protein sequencer (Foster City, USA). Phenylthiohydan- 
toin (PTH)-amino acid from each cycle was analyzed on-line us- 
ing an Applied Biosystems 120A PTH amino acid analyzer. 
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3. RESULTS AND DISCUSSION 
3.1. Purification of p33 
Most of the Ca2+-dependent liposome- 
associated proteins were separated from non- 
associated proteins by centrifugation. These pro- 
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Fig. 1. Elution profile of protein from isoelectric 
chromatofocussing column (Mono P) chromatography. The 
Ca’+-dependent phospholipid-binding protein in the 
supernatant of guinea pig neutrophils was associated with CL- 
containing DPPC liposomes in the presence of 1 mM Ca” and 
dissociated from liposomes by treatment with 5 mM EGTA. 
The dissociated sample was concentrated with (NH&S04 and 
dialysed overnight vs buffer A (25 mM triethanolamine- 
iminodiacetic acid, pH 8.3). The sample was applied to a 
column (200 x 5 mm) of Mono P previously equilibrated with 
buffer A. After washing with buffer A, proteins were eluted 
with buffer B (3.0 ml polybuffer 96, 7.0 ml polybuffer 74 
diluted to a volume of 100 ml iminoacetic acid, pH 5.0). Flow 
rate, 1 ml/min; fraction volume, 1 ml. (A) Elution profile of 
the proteins (A&; (B) Coomassie blue-stained 15% SDS- 
PAGE of eluted proteins; Total, total cytoplasmic protein; 
Sam., phospholipid liposome-associated proteins. 
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teins were dissociated from the phospholipid 
liposomes by treatment with EGTA, and then con- 
centrated with (NHd)zS04. After dialysis against 
buffer A, the sample was applied to a Mono P col- 
umn equipped for high-performance liquid 
chromatography (HPLC) and elution carried out 
with buffer B. Fig.lA shows the elution profile of 
Ca’+-dependent phospholipid-binding proteins 
from Mono P column chromatography. Most of 
the p33 was recovered in fractions 11 and 12, the 
pH of fraction 12 being 7.8 (fig.lB). Fraction 12 
was further purified by gel filtration on TSK 
G3OOOSW. As shown in fig.2, a high degree of 
purification was achieved for p33 retained in frac- 
tion 11, no other proteins being detected in this 
fraction by SDS-PAGE analysis (fig.2, inset). 
3.2. Inhibition of PLA2 by p33 
As shown in fig.3, increasing amounts of p33 
lead to a progressive decrease in the quantity of 
[3H]oleic acid released into the assay supernatant 
by PLAz. Maximal inhibition was 65% whereas 
50% inhibition occurred at 82.5 nM. Pepinsky et 
al. [lo] reported that 72 nM lipocortin I (37 kDa) 
was required for 50% inhibition of PLAz. Khanna 
et al. [30] observed 50% inhibition of PLA2 by 
233 nM lipocortin II but did not find any anti- 
PLAz activity in various calcium-binding proteins 
such as parvalbumin, calmodulin, calregulin, 
FRACTION NO. 
Fig.2. Elution profile of protein from TSK G3OOOSW column 
chromatography. An aliquot (0.2 ml) of the pool from a 
p33-rich fraction from a Mono P column was loaded onto a 
TSK G3OOOSW column, which had been equilibrated with 
50 mM phosphate buffer (pH 7.4). Flow rate, 0.7 ml/min; 
fraction volume, 1 ml. (Inset) 15% SDS-PAGE of fractions 
detected by silver staining. 
33 kDa PROTEIN (pg) 
Fig.3. Phospholipase AZ inhibitory activity of ~33. Aliquots of 
purified p33 were preincubated with 50 ng porcine pancreatic 
PLAz at 4°C for 10 min. The reaction was initiated by adding 
‘H-labeled E. cob membranes as substrate at 4°C and 
terminated 5 min later by addition of 2 N HCI and 100 mg/ml 
of BSA. After centrifugation to remove E. coli membranes, the 
radioactivity of the supernatant was counted in a liquid 
scintillation counter. In all analyses, samples were assayed in 
triplicate and adjusted for nonspecific release by subtracting the 
control value. Results are given as means ? SE from 3 
experiments. 
troponin C, CAB-48 or S-100. Faunel et al. [31] 
reported 50% inhibition of PLA2 by 481 nM en- 
donexin. The inhibitory activity of p33 is therefore 
quite similar to that of lipocortin I. 
K+ + - 
1mM Ca” - + - + 
SPSPSPSP 
actin- -_ .-.- -- 
33k- - - - 
Fig.4. F-Actin binding of ~33. Purified p33 was incubated with 
F-actin for 1 h at room temperature in the binding buffer 
containing 1 mM CaC12 or 1 mM EGTA with or without 
100 mM KCl. After centrifugation, the supernatant (S) and 
pellet (P) were analyzed by SDS-PAGE and Coomassie blue 
staining. 
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3.3. Binding to F-actin 
The p33 bound F-actin in the presence of Ca2+ 
in medium containing no K+, however no binding 
was observed after addition of 1 mM EGTA in 
either the presence or absence of K+ (fig.4). 
Therefore, the binding of p33 to F-actin occurred 
only under certain conditions. 
3.4. Amino acid composition of p33 
The amino acid analysis of purified p33 is de- 
tailed in table 1 together with the amino acid com- 
position of human lipocortin I [32]. Both the 
guinea pig and human polypeptides are very polar 
molecules, with appprox. 30% of the residues be- 
ing charged amino acids: these two proteins 
showed similar compositions. 
3.5. Partial sequence analysis of p33 
Three preliminary attempts to sequence un- 
treated intact p33 were unsuccessful, indicating 
that the N-terminal end of the protein may be 
blocked. Therefore, p33 was digested with trypsin 
or cleaved with CNBr, and the cleavage products 
separated by reverse-phase HPLC on a Cl8 or CA 
column. Fig.5 (panel I) shows peptide maps 
generated from ~33, which were monitored by 
their absorbance at 214 nm. Some of the major 
Table 1 
Amino acid composition (in mol%) of p33 and human 
lipocortin I 
Amino acid P33 Human lipocortin Ia 
Asx 12.4 11.6 
Thr 6.3 6.4 
Ser 1.4 5.5 
GIX 11.0 11.4 
Pro 1.1 2.3 
ClY 6.4 5.5 
Ala 11.3 9.5 
Val 4.3 5.5 
Met 1.9 2.6 
Ile 6.1 6.1 
Leu 10.9 11.6 
Tyr 1.9 3.2 
Phe 1.3 3.5 
His 1.2 1.5 
LYS 10.6 6.8 
Arg 5.3 5.5 
Cys ND 1.2 
Trp ND 0.3 
a From Wallner et al. [32] 
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peaks were subjected to sequence analysis. Fig.5 
(panel II) summarizes the sequences derived from 
the peak fractions. Recently, Wallner et al. [32] 
have cloned and expressed human lipocortin I. For 
each of the guinea pig polypeptides described in 
fig.5 (panel II), we have identified the corre- 
sponding region within the human sequence, based 
on the high degree of sequence homology between 
the two proteins. Out of 53 amino acids that we 
compared, only 14 residues differed (fig.5, panel 
II). From the partial analysis presented here, we 
estimate that the sequences of these guinea pig and 
human proteins are approx. 70% homologous. 
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Fig.5. Partial amino acid sequence of ~33. (I) Tryptic and 
CNBr-cleaved peptide maps of cleavage fragments derived from 
~33. (A) Preparations containing 1OOpg HPLC-purified p33 
were digested with trypsin for 24 h at 37°C and analyzed by 
reverse-phase HPLC on a Crs column. Fractions were 
monitored at 214 nm. (B) These preparations were cleaved with 
CNBr for 15 h at room temperature and analyzed by reverse- 
phase HPLC on a Cd column. Fractions were monitored at 
214 nm. Numbered peaks signify the polypeptides that have 
been sequenced. (II) Comparison of guinea pig neutrophil p33 
and human lipocortin I sequences. Tryptic and CNBr fragments 
were subjected to amino-terminal protein sequence analysis in 
a gas-phase sequenator. Designations for tryptic and CNBr 
fragments correspond to the column peaks in panel I. The 
amino acid sequences of p33 fragments were compared with 
that of human lipocortin I [32]. * Same sequence; % homology 
between human lipocortin I and peptide fragments of p33 is 
indicated; numbers, sequence number of human lipocortin I. 
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Previously, we reported the identification of the 
p33 isolated from guinea pig neutrophils as being 
a Ca2+-dependent phospholipid-binding protein 
[22]. In this study, it was found that p33 binds F- 
actin in the absence of K+ in a Ca2+-dependent 
manner, and that the protein shares functional 
homology with lipocortin I from data on the in- 
hibitory activity for PLA2, amino acid composi- 
tion, and the partial amino acid sequence. 
Together with these data, it is clear that guinea pig 
p33 displays anti-PLAz activity similar to that of 
lipocortin-like protein in other cells. However, the 
isoelectric point of p33 is 7.8 and the protein is 
distributed only in neutrophils [23]: the molecular 
mass, isoelectric point, and cell specificity differ 
from those of human lipocortin-I. Furthermore, 
the content of p33 distributed in neutrophils is very 
high as described in previous papers [22,23]. From 
these facts, the biological roles and relationship 
between p33 in neutrophils and other lipocortin- 
like proteins remain to be elucidated. In connec- 
tion with this, we are now attempting cDNA clon- 
ing of this protein. 
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